ImmunoGen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1981-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.immunogen.com
First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04622774
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇮🇹Policlinico di Modena, Modena, Italy
🇮🇹Azienda Ospedaliera Universitaria Senese, Siena, Italy
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
- Conditions
- Peritoneal CancerEpithelial Ovarian CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT04296890
- Locations
- 🇺🇸
St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States
🇦🇺St John of God Subiaco Hospital, Subiaco, Western Australia, Australia
🇮🇱Shaare Zedek Medical Center, Jerusalem, Israel
Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT02674763
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Baylor Scott & White University Medical Center, Dallas, Texas, United States
🇺🇸The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
- Conditions
- Epithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube CancerOvarian Cancer
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT02631876
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Georgia Regents University (GRU)-Medical College of Georgia (MCG) - Cancer Center, Augusta, Georgia, United States
🇺🇸UCLA Women's Health Clinical Research Unit - OBGYN, Los Angeles, California, United States
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Epithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 264
- Registration Number
- NCT02606305
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇧🇪Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut, Leuven, Belgium
🇺🇸The Ohio State University, Hilliard, Ohio, United States
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01963715
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
- First Posted Date
- 2012-06-01
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 206
- Registration Number
- NCT01609556
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
- Conditions
- Lymphoma, Non-HodgkinChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01534715
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT01237678
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇪🇸Hospital Universitario Virgen del Rocio, Sevilla, Spain
🇬🇧Royal Marsden, London, London, United Kingdom
IMGN901 in Combination With Lenalidomide and Dexamethasone
- Conditions
- Multiple Myeloma
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00991562
- Locations
- 🇺🇸
Comprehensive Cancer Center of the Desert, Palm Springs, California, United States
🇺🇸Weill Medical College, New York, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States